Building on SERENA-6: Advancing the Next Generation of ctDNA-Guided Clinical Programs

• Exploring where ctDNA is already informing clinical decision making today, using SERENA-6 as a leading example of acting on molecular resistance before imaging progression
• Building from established resistance monitoring toward longitudinal ctDNA strategies that can identify molecular progression ahead of imaging and enable earlier clinical decisions
• Looking ahead to emerging approaches such as functional liquid biopsy and integration with imaging to shape the future of ctDNA-guided care

Speakers:

Ryan Hartmaier

Executive Director, Multimodal & Minimally Invasive Biomarkers, Oncology Research & Development

AstraZeneca